1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.

Neuronal pentraxin 1 (NPTX1) is identified as a therapeutically druggable driver of pancreatic cancer metastatic colonization through its action on the receptor AMIGO2, which promotes HIF-1α nuclear ...

Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing, China.

1Yonsei University, College of Medicine, Seoul, Republic of Korea.

1Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer ...

1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, ...

The discovery and characterization of novel WRN helicase inhibitors provides pharmacological validation for the clinical development of WRN inhibitors for the treatment of patients with MSI tumors.

1Department of Oncology, University of Lausanne, Lausanne, Switzerland.

1Department of Cell Growth and Tumor Regulation, Proteo-Science Center, Ehime University, Toon, Japan. Search for other works by this author on: 2Laboratory of Molecular Pharmacology & Developmental ...

1Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 2Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.

Cancer Res (2023) 83 (8_Supplement): LB031.

Abstract. TNG462 is a clinical-stage, MTA-cooperative PRMT5 inhibitor currently being evaluated in an ongoing phase I/II clinical trial for solid tumors with MTAP loss. Approximately 10-15% of all ...